Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib and PEG-Interferon Alfa-2b in Renal Cell Carcinoma
NCT00467077Phase 2Terminated
- Sponsor
- California Cancer Consortium
- Start
- Sep 2004
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in renal cell carcinoma (RCC), sponsored by California Cancer Consortium. Primary endpoint: Progression-Free Survival at 6 months. Started Sep 2004; status: terminated.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00467077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00467077.